Buprenorphine in the Treatment of Opioid Dependence

Medical Comorbidity

Advisory Council for the Elimination of Tuberculosis. Screening for tuberculosis and tuberculosis infection in high-risk populations: Recommendations of the Advisory Council for the Elimination of Tuberculosis. Morbidity and Mortality Weekly Report (44), 1995.

Alter MJ. The prevalence of hepatitis C infection in the United States 1988–1994. New England Journal of Medicine (341):556–562, 1999.

Bayer R and Wilkinson D. Directly observed therapy for tuberculosis: History of an idea. Lancet (345):1,545–1,548, 1995.

Carpenter CC, Cooper DA, and Fischl MA. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel. Journal of the American Medical Association (283):381–390, 2000.

Celentano DD, Vlahov D, Cohn S, Shadle VM, Obasanjo O, and Moore RD. Self-reported antiretroviral therapy in injection drug users. Journal of the American Medical Association (280):544–546, 1998.

Centers for Disease Control and Prevention. Viral Hepatitis B Fact Sheet. Available at www.cdc.gov/ncidod/diseases/hepatitis/b/fact.htm

Chaulk CP, Moore-Rice K, Rizzo R, and Chaisson RE. Eleven years of community-based directly observed therapy for tuberculosis. Journal of the American Medical Association (274):945–951, 1995.

Coutinho RA. HIV and hepatitis C among injecting drug users: Success in preventing HIV has not been mirrored for hepatitis C. British Medical Journal (317):424–425, 1998.

Curtis R, Friedman SR, Neaigus A, Jose B, Goldstein M, and Des Jarlais DC. Implications of directly observed therapy in tuberculosis control measures among IDUs. Public Health Reports (109):319–327, 1994.

Delage G, Infante-Rivard C, Chiavetta JA, Willems B, Pi D, and Fast M. Risk factors for acquisition of hepatitis C virus infection in blood donors: Results of a case-control study. Gastroenterology (116):893–899, 1999.

Garfein RS, Vlahov D, Galai N, Doherty MC, and Nelson KE. Viral infections in short-term injection drug users: The prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. American Journal of Public Health (86):655–661, 1996.

Gordin FM, Matts JP, and Miller C. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. New England Journal of Medicine (337):315, 1997.

Gourevitch MN, Wasserman W, Panero MS, and Selwyn PA. Successful adherence to observed prophylaxis and treatment of tuberculosis among drug users in a methadone program. Journal of Addictive Disorders (15):93–104, 1996.

Graham NM, Galai N, Nelson KE, Astemborski J, Bonds M, and Rizzo RT. Effect of isoniazid chemoprophylaxis on HIV-related mycobacterial disease. Archives of Internal Medicine (156):889–894, 1996.

Gulick RM, Mellors JW, and Havlir D. Treatment with indinavir, zidovudine, lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. New England Journal of Medicine (337):734–739, 1997.

Hecht FM, Wilson IB, Wu AW, Cook RL, and Turner BJ. Optimizing care for persons with HIV infection. Annals of Internal Medicine (131):136–143, 1999.

Horsburgh CR Jr. Advances in the prevention and treatment of Mycobacterium avium disease. New England Journal of Medicine (335):429, 1996.

Libman H and Makadon HJ. HIV. Philadelphia: American College of Physicians, 2000.

Lucas GM, Chaisson RE, and Moore RD. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions. Annals of Internal Medicine (131):81–87, 1999.

Malik AH and Lee WM. Chronic hepatitis B virus infection: Treatment strategies for the next millennium. Annals of Internal Medicine (132):723–731, 2000.

Malotte CK, Rhodes F, and Mais KE. Tuberculosis screening and compliance with return for skin test reading among active drug users. American Journal of Public Health (88):792–796, 1998.

Moore M, Onorato IM, and McCray E. Trends in drug-resistant tuberculosis in the United States 1993–1996. Journal of the American Medical Association (278):833, 1997.

Moreno S, Miralles P, and Diaz MD. Isoniazid preventive therapy in human immunodeficiency virus-infected persons: Long-term effect on development of tuberculosis and survival. Archives of Internal Medicine (157):1,729, 1997.

Novick DM, Reagan KJ, Croxson TS, Gelb AM, Stenger RJ, and Kreek MJ. Hepatitis C virus serology in parenteral drug users with chronic liver disease. Addiction (92):167-711, 1997.

Palella FJ, Delaney KM, and Moorman AC. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England Journal of Medicine (338):853–860, 1998.

Pulido F, Pena JM, and Rubio R. Relapse of tuberculosis after treatment in human immunodeficiency virus-infected patients. Archives of Internal Medicine (157):227, 1997.

O'Connor PG. Complications of injection drug use. In: Proceedings of the 10th Annual Meeting and Symposium of the American Academy of Addiction Psychiatry. Prairie Village, KS: American Academy of Addiction Psychiatry, 17–18, 1999.

O'Connor PG, Molde S, Henry S, Shockor WT, and Schottenfeld RS. Human immunodeficiency virus infection in intravenous drug users: A model for primary care. American Journal of Medicine (93):382–386, 1992.

O'Connor PG and Samet JH. The substance-using human immunodeficiency virus patient: approaches to outpatient management. American Journal of Medicine (101):435–444, 1996.

O'Connor PG, Selwyn PA, and Schottenfeld RS. Medical progress: Medical care for injection drug users with human immunodeficiency virus infection. New England Journal of Medicine (331):450–459, 1994.

Samet JH, Libman H, LaBelle C, Steger K, Lewis R, and Craven DE. A model clinic for the initial evaluation and establishment of primary care for persons infected with human immunodeficiency virus. Archives of Internal Medicine (155):1,629–1,633, 1995.

Samet JH, Stein MD, and O'Connor PG. Models of medical care for HIV-infected drug users. Substance Abuse (16):131–139, 1995.

Strathdee SA, Palepu A, and Cornelisse PGA. Barriers to use of free antiretroviral therapy in injection drug users. Journal of the American Medical Association (280):547–549, 1998.

Wodak A and Crofts N. Once more unto the breach: Controlling hepatitis C in injecting drug users. Addiction (91):181–184, 1996.